Loading...
Rhythm Pharmaceuticals, Inc.
RYTM•NASDAQ
Healthcare
Biotechnology
$87.34
$-1.66(-1.87%)
Rhythm Pharmaceuticals, Inc. (RYTM) Financial Performance & Statements
Review Rhythm Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
68.06%
↑ 68.06%
Operating Income Growth
-44.02%
↓ 44.02%
Net Income Growth
-41.11%
↓ 41.11%
Operating Cash Flow Growth
16.36%
↑ 16.36%
Operating Margin
-126.13%
↓ 126.13%
Gross Margin
89.49%
↑ 89.49%
Net Profit Margin
-124.23%
↓ 124.23%
ROE
-179.82%
↓ 179.82%
ROIC
-62.80%
↓ 62.80%
Rhythm Pharmaceuticals, Inc. (RYTM) Financial Statements
Explore quarterly and annual reports for Rhythm Pharmaceuticals, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $41.83M | $33.25M | $29.08M | $25.97M |
| Cost of Revenue | $3.79M | $3.83M | $3.12M | $3.00M |
| Gross Profit | $38.04M | $29.42M | $25.95M | $22.97M |
| Gross Profit Ratio | $0.91 | $0.88 | $0.89 | $0.88 |
| R&D Expenses | $41.17M | $37.93M | $30.02M | $128.47M |
| SG&A Expenses | $38.13M | $35.38M | $36.41M | $34.38M |
| Operating Expenses | $79.30M | $73.31M | $66.43M | $162.86M |
| Total Costs & Expenses | $83.08M | $77.14M | $69.56M | $165.85M |
| Interest Income | $3.52M | $4.05M | $4.10M | $3.05M |
| Interest Expense | $5.45M | $5.24M | $4.60M | $4.75M |
| Depreciation & Amortization | $383000.00 | $385000.00 | $391000.00 | $405000.00 |
| EBITDA | -$37.55M | -$38.36M | -$26.79M | -$135.91M |
| EBITDA Ratio | -$0.90 | -$1.15 | -$0.92 | -$5.23 |
| Operating Income | -$41.26M | -$43.88M | -$40.48M | -$139.89M |
| Operating Income Ratio | -$0.99 | -$1.32 | -$1.39 | -$5.39 |
| Other Income/Expenses (Net) | -$2.13M | -$100000.00 | $8.70M | -$1.19M |
| Income Before Tax | -$43.38M | -$43.98M | -$31.78M | -$141.07M |
| Income Before Tax Ratio | -$1.04 | -$1.32 | -$1.09 | -$5.43 |
| Income Tax Expense | -$90000.00 | -$344000.00 | $479000.00 | $300000.00 |
| Net Income | -$43.29M | -$44.97M | -$32.26M | -$141.37M |
| Net Income Ratio | -$1.03 | -$1.35 | -$1.11 | -$5.44 |
| EPS | -$0.77 | -$0.71 | -$0.53 | -$2.35 |
| Diluted EPS | -$0.77 | -$0.71 | -$0.53 | -$2.35 |
| Weighted Avg Shares Outstanding | $61.60M | $61.22M | $61.01M | $60.14M |
| Weighted Avg Shares Outstanding (Diluted) | $61.60M | $61.22M | $61.01M | $60.14M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan